Stock Code: 603707 Stock Abbreviation: King-friend Announcement No.: 2026-048

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.

Announcement on the Subsidiary's Receipt of the U.S. FDA Approval Letter for an Additional Manufacturing Site of Adalimumab Injection

The Board of Directors and all directors of the Company warrant that there are no false records, misleading statements or material omissions in the contents of this announcement, and they shall bear individual and joint and several legal liability for the truthfulness, accuracy and completeness of its contents.

Emerge Bioscience Pte. Ltd. ("Emerge"), a subsidiary of Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as "King-friend Pharma" or the "Company"), has recently received from the U.S. Food and Drug Administration (hereinafter referred to as the "U.S. FDA") an approval letter for an additional manufacturing site of Adalimumab Injection (40 mg/0.8 mL, single-dose) (BLA No.: 761216), which approves the manufacturing of the product at the site of Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. The relevant details are hereby announced as follows:

I. Basic Information about the Drug

(I) Drug Name: Adalimumab Injection

(II) Indications

1. Rheumatoid arthritis (adults): for use in patients with moderately to severely active disease, to reduce signs and symptoms, induce major clinical response, inhibit the progression of structural damage, and improve physical function;
2. Polyarticular juvenile idiopathic arthritis (patients aged 2 years and above): for use in patients with moderately to severely active disease, to reduce signs and symptoms;
3. Psoriatic arthritis (adults): for use in patients with active disease, to reduce signs and symptoms, inhibit the progression of structural damage, and improve physical function;
4. Ankylosing spondylitis (adults): for use in patients with active disease, to reduce signs and symptoms;
5. Crohn's disease (adults and children aged 6 years and above): for the treatment of moderately to severely active disease;
6. Ulcerative colitis (adults): for the treatment of moderately to severely active disease;
7. Chronic plaque psoriasis (adults): for patients with moderate to severe disease who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate;
8. Hidradenitis suppurativa (patients aged 12 years and above): for the treatment of moderate to severe disease;
9. Non-infectious uveitis (adults and children aged 2 years and above): for the treatment of intermediate, posterior and panuveitis.

(III) Dosage Form: Injection

(IV) Strength:40 mg/0.8 mL

(V) BLA No.:761216

(VI) Applicant: Emerge Bioscience Pte. Ltd.

II. Other Relevant Information about the Drug

The Company has recently received notification from the U.S. FDA that the Biologics License Application (BLA) submitted by its subsidiary Emerge to the U.S. FDA for an additional manufacturing site of Adalimumab Injection (40 mg/0.8 mL) has been approved, permitting manufacturing at the site of Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.

Adalimumab Injection, as a biosimilar, was approved by the U.S. FDA for marketing on December 17, 2021, under the trade name YUSIMRY. The product was originally held by Coherus BioSciences.

As of the date hereof, the Company has invested approximately RMB 13,777.78 ten-thousand yuan (approximately RMB 137.78 million) in research and development expenses for the project to transfer the manufacturing site of Adalimumab Injection.

III. Impact on the Company

The newly approved product further enriches the Company's international product pipeline and strengthens the Company's international market presence. If the product is subsequently launched and sold in the U.S. market, it is expected to have a positive impact on the Company's operating performance.

IV. Risk Warning

The Company attaches great importance to drug R&D and strictly controls the quality and safety of drug R&D, manufacturing and sales. However, the manufacturing and sale of the product are susceptible to uncertainties such as national policies and market conditions, and may be subject to circumstances such as under-performance of sales. All investors are advised to make cautious decisions and pay attention to the prevention of investment risks.

It is hereby announced.

Board of Directors of Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.

September 2, 2026